Document:

QuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 10.1    
    

Confidential
Materials omitted and filed separately with the

Securities and Exchange Commission. Asterisks denote omissions. 

AMENDMENT TO RESEARCH AND LICENSE AGREEMENT  

        WHEREAS, Trustees of Boston University of Massachusetts, a non-profit corporation with offices at 715 Albany Street, 560, Boston, Massachusetts
(hereinafter referred to as "UNIVERSITY") and NitroMed, Inc., a Delaware corporation with its principle office at 12 Oak Park Drive, Bedford, Massachusetts 01730 (hereinafter referred to as
"NITROMED") for certain SPONSORED RESEARCH PROGRAMS to be sponsored by NITROMED and performed by UNIVERSITY as set forth in the Research and License Agreement between Trustees of Boston University and
NitroMed, Inc. effective June 1, 1993 (hereinafter referred to as "AGREEMENT"). 

        WHEREAS,
NITROMED desires to sponsor and UNIVERSITY desires to perform an additional SPONSORED RESEARCH PROGRAM as described in the attached Exhibit A. 

        WHEREAS,
NITROMED and UNIVERSITY mutually desire to amend the AGREEMENT to reflect the additional SPONSORED RESEARCH PROGRAM to be sponsored by NITROMED and performed by UNIVERSITY. 

        WHEREAS,
for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the UNIVERSITY and NITROMED hereby agree to amend the AGREEMENT as follows: 

	1.
	Add
the RESEARCH PROPOSAL entitled "S-Nitrosothials in the Metabolism and Action of Exogenous Nitric Oxide Donors" which is attached hereto as Exhibit A and which
shall be a duly authorized SPONSORED RESEARCH PROGRAM as that term is defined in the AGREEMENT.

	2.
	NITROMED
shall fund the research described in Exhibit A in accordance with the budget attached hereto as Exhibit B. 

        Except
as specifically provided herein, the AGREEMENT as originally executed subject to any prior amendments is hereby ratified and confirmed. 

        IN
WITNESS WHEREOF, the parties have caused this Amendment to be executed by their duly authorized representatives. 

	By:	 	/s/  MICHAEL D. LOBERG      
	 	By:	 	/s/  JOSEPH BARABINO      

	Name:	 	Michael D. Loberg
	 	Name:	 	Joseph Barabino

	Title:	 	CEO
	 	Title:	 	Director of Research Administration

	Date:	 	12/2/02
	 	Date:	 	12/3/02

S-Nitrosothiols in the Metabolism and Action of Exogenous Nitric Oxide Donors  

Exhibit A

        I
would like to propose the following experiments that address identifying the potential S-nitrosothiol intermediate(s) involved in nitrate metabolism. All experiments will
be performed using HepG2or G3 cells and rat liver (either following intravenous infusion or isolated perfusion of the liver with the nitrate compound of interest). In each case, cells will be exposed
to isosorbide mononitrate or a nitrated NSAID (SINOD). 

	1.
	Determine
S-nitrosoproteins in hepatocyte or liver lysates using the Snyder method (Jaffrey et al., Nature Cell Biol 2001;3:193-197).

	2.
	Determine
low-molecular-weight S-nitrosothiols using a modified Snyder approach, ascorbate-dependent release of NO detected by DAF (in hepatocyte experiments),
and HPLC of resulting thiols. The same experiments will be performed in the presence of a copper chelator to increase the steady-state concentrations of RSNOs (in hepatocytes and in rats; in the
latter, in liver lysates and in plasma).

	3.
	Inhibit
PDI with antisense ODNs (in hepatocyte experiments) to determine role of this cell-surface enzyme pool on export of intracellular low-molecular-weight
RSNOs; this approach should also boost the intracellular concentration of these RSNOs to facilitate their detection and identification.

	4.
	Deplete
intracellular thiol pools with buthionine sulfoximine and determine the consequences of this depletion on mononitrate metabolism to bioactive NO.

	5.
	Use
mass spectroscopy to determine the hepatocyte/liver RSNO pools, separating lysates in the presence of a copper chelator by FPLC/HPLC. These experiments would be performed with
Catherine Costello, the Director of our mass spec facility here. (She has performed this type of analysis for me in the past.) 

S-Nitrosothiols in the Metabolism and Action of Exogenous Nitric Oxide Donors  

EXHIBIT
B 

Budget

	Salary	 	$	[**	]
	Fringe	 	$	[**	]
	Supplies	 	$	[**	]
	Total DC	 	$	[**	]
	IDC @ 25%	 	$	[**	]
	TOTAL	 	$	[**	]

AMENDMENT 2 TO RESEARCH AND LICENSE AGREEMENT  

        WHEREAS, Trustees of Boston University of Massachusetts, a non-profit corporation with offices at 715 Albany Street, 560, Boston, Massachusetts
(hereinafter referred to as "UNIVERSITY") and NitroMed, Inc., a Delaware corporation with its principle office at 125 Spring Street, Lexington, Massachusetts 02421 (hereinafter referred to as
"NITROMED") for certain SPONSORED RESEARCH PROGRAMS to be sponsored by NITROMED and performed by UNIVERSITY as set forth in the Research and License Agreement between Trustees of Boston University and
NitroMed, Inc. effective June 1, 1993 (hereinafter referred to as "AGREEMENT"). 

        WHEREAS,
NITROMED desires to sponsor and UNIVERSITY desires to perform an additional SPONSORED RESEARCH PROGRAM as described in the attached Exhibit A. 

        WHEREAS,
NITROMED and UNIVERSITY mutually desire to amend the AGREEMENT to reflect the additional SPONSORED RESEARCH PROGRAM to be sponsored by NITROMED and performed by UNIVERSITY. 

        WHEREAS,
for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the UNIVERSITY and NITROMED hereby agree to amend the AGREEMENT as follows: 

	1.
	Add
the RESEARCH PROPOSAL entitled "Assessment of the Antioxidant Potential of NO Donors and Hydralazine" which is attached hereto as Exhibit A and which shall be a duly
authorized SPONSORED RESEARCH PROGRAM as that term is defined in the AGREEMENT.

	2.
	NITROMED
shall fund the research described in Exhibit A in accordance with the budget attached hereto as Exhibit B. 

        Except
as specifically provided herein, the AGREEMENT as originally executed subject to any prior amendments is hereby ratified and confirmed. 

        IN
WITNESS WHEREOF, the parties have caused this Amendment to be executed by their duly authorized representatives. 

	By:	 	/s/  L. GORDON LETTS      
	 	By:	 	/s/  JOSEPH BARABINO      

	Name:	 	L. Gordon Letts
	 	Name:	 	Joseph Barabino

	Title:	 	CSO & Senior VP R&D
	 	Title:	 	Director, Office of Research Administration

	Date:	 	1-31-2005
	 	Date:	 	2/19/05

Exhibit A  

Assessment of the Antioxidant Potential of NO Donors and Hydralazine  

        The major goal of this research project is to provide insight into the molecular mode of action of BiDil, a combination comprising isosorbide dinitrate (ISDN) and
hydralazine. Results from these investigations are expected to provide a better rationale for the observed clinical effectiveness of this drug in the setting of heart failure and thus aid in
NitroMed's scientific development/marketing efforts during and after the launch. A key aspect addressed in previous studies with hydralazine has been its ability to prevent the development of nitrate
tolerance and to act as an antioxidant. The latter forms the basis for the current working hypothesis that BiDil is particularly effective in African Americans because of a higher propensity/degree of
oxidative stress in this compared to other ethnic groups. 

        Based
on the assumption that some if not all of the beneficial actions of hydralazine and ISDN on cardiac performance are due to an effect that is only observable under in vivo
conditions, the majority of the studies will be performed in tissues sampled from experimental rodent models. These investigations will be complemented by a limited set of in vitro studies. Healthy
male Wistar rats will serve as an initail screen to investigate the effects of ISDN and hydralazine, alone and in combination, on NO-related metabolites (S-nitrosothiol,
N-nitrosamine and heme-nitrosyl species, as well as nitrite and nitrate; BiDil's NObonome) and a broad array of key antioxidant enzymes (e.g. SOD, catalase, GPx, GR, TrX),
reactive oxygen species (e.g. hydrogen peroxide, superoxide) as well as biologically relevant oxidation products (e.g. isoprostanes, MDA, LPO, nitrotyrosine) and other biomarkers of oxidative stress
such as cellular GSH/GSSG and Asc/DHA ratios. In addition, NO availability will be assessed by quantification of cGMP concentrations. Wherever possible, assays will be established in/adapted to the
96-well plate design to allow for high throughput, and transferred to NitroMed after study completion. All of the above measurements will be carried out in blood (plasma, RBCs) and select
tissues (heart, aorta, vena cava, liver, kidney). The combined assessment of the drugs' NObonome and the profile of direct and indirect antioxidative effects should provide a powerful tool to evaluate
the contributions of individual components to the overall biochemical/pharmacological effect of BiDil. In a second step the effects of ISDN, hydralazine and their combination on the above parameters
will be investigated in select animal models of disease. Since heart failure as a consequence of hypertension appears to develop more frequently in African Americans than in other populations
[**] 

        The
overall hypothesis of this project is that [**]. If this assumption is correct, the results of these studies [**] 

Exhibit B  

Budget  

	Title of Research Project:	 	Assessment of the Antioxidant Potential of NO Donors and Hydralazine	 	 	 	 
	Study Period:	 	Jan 2, 2005 — Dec 30, 2005	 	 	 	 
	Principal Investigator:	 	Martin Feelisch, PhD

Professor of Medicine, Professor of Biochemistry

Phone: 617-414-8150; e-mail: feelisch@bu.edu	 	 	 	 
	Location:	 	Evans Biomedical Research Institute, X 128/129

Boston University School of Medicine

650 Albany Street, Boston, MA 02118	 	 	 	 
	Budget Categories:	 	Equipment	 	$	[**	]
	 	 	[**]	 	 	 	 
	 	 	Animals and husbandry	 	$	[**	]
	 	 	Controls: [**]	 	 	 	 
	 	 	Disease models: [**]	 	 	 	 
	 	 	Personnel	 	$	[**	]
	 	 	[**]	 	 	 	 
	 	 	Chemicals and consumables	 	$	[**	]
	 	 	[**]	 	 	 	 
	 	 	 	 	
	 
	Total Project Costs:	 	 	 	$	[**	]

QuickLinks

Exhibit 10.1QuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 4.4    
    

SECOND SUPPLEMENTAL INDENTURE  

        SECOND SUPPLEMENTAL INDENTURE (this "Supplemental Indenture"), dated as of January 10, 2005, among Chevys
Restaurants, LLC, a Delaware limited liability company (the "Guaranteeing Subsidiary"), a subsidiary of Real Mex Restaurants, Inc. (or its
permitted successor), a Delaware corporation (the "Company"), the Company, the other Guarantors (as defined in the Indenture referred to herein) and
Wells Fargo Bank, N.A., as Trustee under the Indenture referred to below (the "Trustee"). 

WITNESSETH  

        WHEREAS, the Company has heretofore executed and delivered to the Trustee an indenture (the "Indenture"), dated as
of March 31, 2004 providing for the issuance of 10% Senior Secured Notes due 2004 (the "Notes"); 

        WHEREAS,
the Indenture provides that under certain circumstances the Guaranteeing Subsidiary shall execute and deliver to the Trustee a supplemental indenture pursuant to which the
Guaranteeing Subsidiary shall unconditionally guarantee all of the Company's Obligations under the Notes and the Indenture on the terms and conditions set forth herein (the
"Note Guarantee"); and 

        WHEREAS,
pursuant to Section 9.01 of the Indenture, the Trustee is authorized to execute and deliver this Supplemental Indenture. 

        NOW,
THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt of which is hereby acknowledged, the Guaranteeing Subsidiary and the Trustee
mutually covenant and agree for the equal and ratable benefit of the Holders of the Notes as follows: 

        1.    CAPITALIZED TERMS.    Capitalized terms used herein without definition shall have the meanings assigned to them
in the Indenture. 

        2.    AGREEMENT TO GUARANTEE.    The Guaranteeing Subsidiary hereby agrees to provide an unconditional Guarantee on
the terms and subject to the conditions set forth in the Note Guarantee and in the Indenture including but not limited to Article 11 thereof. 

        3.    NO RECOURSE AGAINST OTHERS.    No past, present or future director, officer, employee, incorporator, stockholder
or agent of the Guaranteeing Subsidiary, as such, shall have any liability for any obligations of the Company or any Guaranteeing Subsidiary under the Notes, any Note Guarantees, the Indenture or this
Supplemental Indenture or for any claim based on, in respect of, or by reason of, such obligations or their creation. Each Holder of the Notes by accepting a Note waives and releases all such
liability. The waiver and release are part of the consideration for issuance of the Notes. Such waiver may not be effective to waive liabilities under the federal securities laws and it is the view of
the SEC that such a waiver is against public policy. 

        4.    NEW YORK LAW TO GOVERN.    THE INTERNAL LAW OF THE STATE OF NEW YORK SHALL GOVERN AND BE USED TO CONSTRUE THIS
SUPPLEMENTAL INDENTURE WITHOUT GIVING EFFECT TO APPLICABLE PRINCIPLES OF CONFLICTS OF LAW TO THE EXTENT THAT THE APPLICATION OF THE LAWS OF ANOTHER JURISDICTION WOULD BE REQUIRED THEREBY. 

        5.    COUNTERPARTS.    The parties may sign any number of copies of this Supplemental Indenture. Each signed copy
shall be an original, but all of them together represent the same agreement. 

        6.    EFFECT OF HEADINGS.    The Section headings herein are for convenience only and shall not affect the
construction hereof. 

        7.    THE TRUSTEE.    The Trustee shall not be responsible in any manner whatsoever for or in respect of the validity
or sufficiency of this Supplemental Indenture or for or in respect of the recitals contained herein, all of which recitals are made solely by the Guaranteeing Subsidiary and the Company. 

[signature page follows] 

        IN
WITNESS WHEREOF, the parties hereto have caused this Supplemental Indenture to be duly executed and attested, all as of the date first above written. 

	Dated: January 10, 2005	 	 	 	 
	 	 	 	 	 
	 	 	CHEVYS RESTAURANTS, LLC
	

 	
 	

 	

 	

 
	 	 	By:	/s/  CHARLES RINK      

	 	 	 	Name:	Charles Rink
	 	 	 	Title:	President
	

 	
 	

 	

 	

 
	 	 	REAL MEX RESTAURANTS, INC.
	

 	
 	

 	

 	

 
	 	 	By:	/s/  FREDERICK F. WOLFE      

	 	 	 	Name:	Frederick F. Wolfe
	 	 	 	Title:	President
	

 	
 	

 	

 	

 
	 	 	ACAPULCO RESTAURANTS, INC.

EL TORITO RESTAURANTS, INC.

EL TORITO FRANCHISING COMPANY

ACAPULCO RESTAURANT OF VENTURA

ACAPULCO RESTAURANT OF WESTWOOD

ACAPULCO RESTAURANT OF DOWNEY

MURRAY PACIFIC

ACAPULCO RESTAURANTS OF ENCINITAS, INC

ACAPULCO RESTAURANT OF MORENO VALLEY, INC.

EL PASO CANTINA, INC.

REAL MEX FOODS, INC.

TARV, INC.

ALA DESIGN, INC.

ACAPULCO MARK CORP.

CKR ACQUISITION CORP.
	

 	
 	

 	

 	

 
	 	 	By:	/s/  FREDERICK F. WOLFE      

	 	 	 	Name:	Frederick F. Wolfe
	 	 	 	Title:	President
	

 	
 	

 	

 	

 
	 	 	WELLS FARGO BANK, N.A.

as Trustee
	

 	
 	

 	

 	

 
	 	 	By:	/s/  MADELIENA J. HALL      
 Authorized Signatory
	 	 	 	 	 

QuickLinks

Exhibit 4.4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00084-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00084-of-00352.parquet"}]]